Capital Fund Management (CFM)
CLDX icon

Capital Fund Management (CFM)’s Celldex Therapeutics CLDX Stock Holding History

Capital Fund Management (CFM)’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-967
Closed -$404K – 1478
2015
Q1 		$404K Buy
+967
New +$346K 0.01% 1124
2014
Q1 		– Sell
-1,040
Closed -$378K – 1721
2013
Q4 		$378K Buy
+1,040
New +$401K ﹤0.01% 1360

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Fund Management (CFM)'s CLDX Position: Q2 2025 in Review

Capital Fund Management (CFM) sold out of Celldex Therapeutics (CLDX) in Q2 2025, closing a stake of 15,501 shares — an estimated $281K sold.

Capital Fund Management (CFM) first reported a position in CLDX in Q3 2013 and held it in 9 quarters. The position peaked at $13.3M in Q4 2013. 180 funds tracked by Wall St. Rank hold CLDX as of Q2 2025.

  • Capital Fund Management (CFM) reported no remaining Celldex Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 15,501 Celldex Therapeutics shares in Q2 2025, an estimated $281K.
  • Capital Fund Management (CFM) first reported a position in Celldex Therapeutics in Q3 2013 and held it in 9 quarters.
  • Capital Fund Management (CFM)'s Celldex Therapeutics position peaked at $13.3M in Q4 2013.
  • 180 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2025, filed 13 Aug 2025.